We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effects of Bosentan in Treatment of Severe Pulmonary Hypertension Related to Congenital Heart Disease.
- Authors
LU Yi-bing; DAI Hai-long; GUANG Xue-feng; ZHANG Wei-hua; XUE Qiang; DENG Jie
- Abstract
Objective To observe the clinical efficacy of bosentan in treatment of severe pulmonary hypertension related to congenital heart disease (CHD-PAH). Methods 5 patients with severe CHD-PAH patients received bosentan therapy, then pulmonary artery pressure, pulmonary vascular resistance (PVR), 6min walk test, right ventricular end-systolic diameter (RVSD) changes were observed and statistically analyzed after six months medication. Results Pulmonary arterial systolic pressure (sPAP) was significantly decreased from (96 ± 11) mmHg to (86 ± 10) mmHg, P<0.01. pulmonary arterial diastolic pressure (dPAP) was significantly decreased from (56 ± 10) mmHg to (46 ± 9) mmHg (P<0.01), pulmonary arterial mean pressure (mPAP) was significantly decreased from (73 ± 11) mmHg to (59 ±10) mmHg (P < 0.05), pulmonary vascular resistance was significantly decreased from (17.8 ± 1.9) Wood to (13.1 ± 1.7) Wood (P<0.01) 6min walk test was improved from (136 ± 40) m to (198 ± 55) m, P<0.01. right ventricular end-systolic diameter significantly decreased from (40 ± 5) mm to (36 ± 6) mm after 6 months therapy (P<0.05) . Conclusion Bosentan can decrease pulmonary arterial systolic pressure, improve exercise tolerance, improve right ventricular function in patients with severe CHD-PAH.
- Subjects
PULMONARY hypertension; CONGENITAL heart disease; PULMONARY artery diseases; PULMONARY blood vessels; EXERCISE physiology
- Publication
Journal of Kunming Medical University / Kunming Yike Daxue Xuebao, 2014, Vol 35, Issue 2, p15
- ISSN
2095-610X
- Publication type
Article